21. ミトコンドリア病 Mitochondrial disease Clinical trials / Disease details


臨床試験数 : 39 薬物数 : 42 - (DrugBank : 32) / 標的遺伝子数 : 47 - 標的パスウェイ数 : 67

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05650229
(ClinicalTrials.gov)
December 13, 20226/12/2022Efficacy of KL1333 in Adult Patients With Primary Mitochondrial DiseaseAn Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Adaptive Study of the Efficacy of KL1333 in Adult Patients With Primary Mitochondrial DiseasePrimary Mitochondrial DiseaseDrug: KL1333;Drug: PlaceboAbliva ABNULLRecruiting18 YearsN/AAll180Phase 2Denmark;United Kingdom
2NCT04643249
(ClinicalTrials.gov)
November 10, 202013/11/2020Drug-drug Interaction Study of KL1333 in Healthy SubjectsA Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy SubjectsMitochondrial DiseaseDrug: KL1333;Drug: Flurbiprofen;Drug: Dextromethorphan;Drug: Bupropion;Drug: Midazolam injection;Drug: Omeprazole;Drug: Caffeine;Drug: RepaglinideAbliva ABNULLCompleted18 Years65 YearsAll14Phase 1United Kingdom
3NCT03888716
(ClinicalTrials.gov)
March 18, 201919/3/2019A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial DiseaseA Phase Ia/Ib, Multiple-site Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KL1333 After a Single and Multiple Ascending Oral Doses in Healthy Subjects and Patients With Primary Mitochondrial DiseaseMitochondrial Diseases;Mitochondrial Respiratory Chain Deficiencies;MELAS Syndrome;Mitochondrial MyopathiesDrug: KL1333;Drug: Placebo Oral TabletAbliva ABNULLCompleted18 Years75 YearsAll72Phase 1United Kingdom